Global Non-Invasive Prenatal Testing Market Size, Trends & Growth Opportunity, By Component (Instruments, Kits and Reagents, Services), By Application (Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner syndrome, other), By End User (Hospitals, Diagnostic Labs) By Region and Forecast till 2027.
Report ID : QR1001370 | Industries : Healthcare | Published On :January 2022 | Page Count : 235Global Non-Invasive Prenatal Testing Market
The Global Non-Invasive Prenatal Testing market is projected to grow from USD 1,490 million in 2020 to USD 3,396 million by 2026 at a CAGR of over 14.4% during the forecast period.
Non-invasive prenatal testing is a technique for determining the likelihood of a fetus being born with chromosomal abnormalities like Trisomy 21, Trisomy 18, or Trisomy 13. This test examines small DNA fragments that circulate in a pregnant woman's blood. Furthermore, non-invasive prenatal tests' advantages over other prenatal tests, such as their non-invasive nature, higher accuracy, and shorter procedure time, are expected to propel the global NIPT market forward during the forecast period.
Market Drivers
With increasing maternal age, there is a higher risk of chromosomal abnormalities.
The age of a woman at the time of delivery is referred to as her maternal age. Increasing maternal age can lead to a variety of health issues, including decreased fertility, high blood pressure, and an increased risk of miscarriage, stillbirth, and maternal death. Furthermore, increasing maternal age can increase the risk of genetic disorders in babies due to improper chromosomal division.
Know more about this report: request for sample pages
Market Restraints
High Cost of Tests to Limit Market Growth the high cost of these tests, which makes them relatively unaffordable in many developing countries, is likely to limit their use. According to a Future Medicine article, the average cost of NIPT in India is between USD 350 and USD 400. As a result, their uptake in developing countries has been limited.
Impact of COVID-19
The COVID-19 outbreak has had a minor impact on the market for non-invasive prenatal testing. Several manufacturing companies are in close contact with the US Food and Drug Administration to keep them informed of any disruptions in the supply chain. Furthermore, several research studies are being conducted to determine the market impact of COVID-19. According to a SeraCare report, during the COVID pandemic, in-vitro diagnostics manufacturers and clinical testing laboratories collaborate with research organizations to determine the impact of SARS-CoV-2 infection on pregnancy and congenital disabilities in newborns, as well as the need for Non Invasive prenatal testing.
Market Segmentation
The Global Non-Invasive Prenatal Testing Market is segmented into Component, Application, Distribution Channel and Growing System. By Component such as Instruments, Kits and Reagents, Services. By Application such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner syndrome, other. By End User such as Hospitals, Diagnostic Labs.
Regional Analysis
Global Non-Invasive Prenatal Testing Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. During the forecast period. During the forecast period, North America is expected to be the market leader in the NIPT market. The region's high preterm birth rate, high maternal mortality rate, and rising incidences of chromosomal abnormalities will almost certainly increase test adoption and demand.
According to the Trisomy 18 Foundation, Edwards syndrome (Trisomy 18) error occurs in approximately one out of every 2,500 pregnancies in the United States and one out of every 6,000 live births. North America is home to several major companies from around the world working on foetal and neonatal care, with direct distribution channels and third-party services for distribution in relation to medical/hospital requirements.
Key Players
Various key players are listed in this report such as Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)
Market Taxonomy
By Component
- Instruments
- Kits and Reagents
- Services
By Application
- Down syndrome (trisomy 21)
- Edwards syndrome (trisomy 18)
- Patau syndrome (trisomy 13)
- Turner syndrome
- Other
By End User
- Hospitals
- Diagnostic Labs
By Region
- North America
- Latin America
- Europe
- China
- Asia Pacific
- Middle East & Africa
Key Questions Addressed by the Report
- What are the Key Opportunities in Global Non-Invasive Prenatal Testing Market?
- What will be the growth rate from 2020 to 2027?
- Which segment/region will have highest growth?
- What are the factors that will impact/drive the Market?
- What is the competitive Landscape in the Industry?
- What is the role of key players in the value chain?
Global Non-Invasive Prenatal Testing Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Non-Invasive Prenatal Testing Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Non-Invasive Prenatal Testing Market, By Component
5.1 Y-o-Y Growth Comparison, By Component
5.2 Global Non-Invasive Prenatal Testing Market Share Analysis, By Component
5.3 Global Non-Invasive Prenatal Testing Market Size and Forecast, By Component
5.3.1 Instruments
5.3.2 Kits and Reagents
5.3.3 Services
6 Global Non-Invasive Prenatal Testing Market, By Application
6.1 Y-o-Y Growth Comparison, By Application
6.2 Global Non-Invasive Prenatal Testing Market Share Analysis, By Application
6.3 Global Non-Invasive Prenatal Testing Market Size and Forecast, By Application
6.3.1 down syndrome (trisomy 21)
6.3.2Edwards syndrome (trisomy 18)
6.3.3 Patau syndrome (trisomy 13)
6.3.4 Turner syndrome
Other 7 Global Non-Invasive Prenatal Testing Market, By End User
7.1 Y-o-Y Growth Comparison, By End User
7.2 Global Non-Invasive Prenatal Testing Market Share Analysis, By End User
7.3 Global Non-Invasive Prenatal Testing Market Size and Forecast, By End User
7.3.1 Hospitals
7.3.2 Diagnostic Labs
8 Global Non-Invasive Prenatal Testing Market, By Region
8.1 Global Non-Invasive Prenatal Testing Market Share Analysis, By Region
8.2 Global Non-Invasive Prenatal Testing Market Share Analysis, By Region
8.3 Global Non-Invasive Prenatal Testing Market Size and Forecast, By Region
9 North America Non-Invasive Prenatal Testing Market Analysis and Forecast (2021-2027)
9.1 Introduction
9.2 North America Non-Invasive Prenatal Testing Market Share Analysis, By Component
9.3 North America Non-Invasive Prenatal Testing Market Size and Forecast, By Application
9.4 North America Non-Invasive Prenatal Testing Market Size and Forecast, By End User
9.6 North America Non-Invasive Prenatal Testing Market Size and Forecast, By Country
9.7.1 U.S.
9.7.2 Canada
9.7.3 Mexico
10 Europe Non-Invasive Prenatal Testing Market Analysis and Forecast (2021-2027)
10.1 Introduction
10.2 Europe Non-Invasive Prenatal Testing Market Share Analysis, By Component
10.3 Europe Non-Invasive Prenatal Testing Market Size and Forecast, By Application
10.4 Europe Non-Invasive Prenatal Testing Market Size and Forecast, By End User
10.6 Europe Non-Invasive Prenatal Testing Market Size and Forecast, By Country
10.6.1 Germany
10.6.2 France
10.6.3 UK
10.6.4. Rest of Europe
11 Asia Pacific Non-Invasive Prenatal Testing Market Analysis and Forecast (2021-2027)
11.1 Introduction
11.2 Asia Pacific Non-Invasive Prenatal Testing Market Share Analysis, By Component
11.3 Asia Pacific Non-Invasive Prenatal Testing Market Size and Forecast, By Application
11.4 Asia Pacific Non-Invasive Prenatal Testing Market Size and Forecast, By End User
11.6 Asia Pacific Non-Invasive Prenatal Testing Market Size and Forecast, By Country
11.6.1 China
11.7.2 Japan
11.8.3 India
11.8.4. Rest of Asia Pacific
12 Latin America Non-Invasive Prenatal Testing Market Analysis and Forecast (2021-2027)
12.1 Introduction
12.2 Latin America Non-Invasive Prenatal Testing Market Share Analysis, By Component
12.3 Latin America Non-Invasive Prenatal Testing Market Size and Forecast, By Application
12.4 Latin America Non-Invasive Prenatal Testing Market Size and Forecast, By End User
12.6 Latin America Non-Invasive Prenatal Testing Market Size and Forecast, Country
12.7.1. Brazil
12.8.2. Rest of Latin America
13 Middle East Non-Invasive Prenatal Testing Market Analysis and Forecast (2021-2027)
13.1 Introduction
13.2 Middle East Non-Invasive Prenatal Testing Market Share Analysis, By Component
13.3 Middle East Non-Invasive Prenatal Testing Market Size and Forecast, By Application
13.4 Middle East Non-Invasive Prenatal Testing Market Size and Forecast, By End User
13.6 Middle East Non-Invasive Prenatal Testing Market Size and Forecast, By Country
13.7.1. Saudi Arabia
13.8.2. UAE
13.8.3. Egypt
13.9.4. Kuwait
13.10.5. South Africa
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 Illumina, Inc
15.1.1 Overview
15.1.2 Components
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2. Thermo Fisher Scientific Inc
15.2.1 Overview
15.2.2 Components
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. GE Healthcare
15.3.1 Overview
15.3.2 Components
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 BGI
15.4.1 Overview
15.4.2 Components
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Agilent Technologies, Inc.
15.5.1 Overview
15.5.2 Components
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 F. Hoffmann-La Roche Ltd
15.6.1 Overview
15.6.2 Components
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 PerkinElmer Inc.
15.7.1 Overview
15.7.2 Components
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Laboratory Corporation of America Holdings
15.8.1 Overview
15.8.2 Components
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
16.8 Natera, Inc.
16.8.1 Overview
16.8.2 Components
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
17.8 Yourgene Health.
17.8.1 Overview
17.8.2 Components
17.8.3 Key Financials
17.8.4 Business Segment & Geographic Overview
17.8.5 Key Market Developments
17.8.6 Key Strategies